Conestoga Capital Advisors, an asset management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The letter reports a positive market shift towards Small Caps, with the Russell 2000 Index achieving its best first half since 1991 and the Russell 2000 Growth Index up 25.7% in Q2, fueled by AI enthusiasm and semiconductor stocks. However, market leadership was uneven, mirroring the Tech Bubble: high-beta stocks outperformed while high-quality companies lagged, affecting Conestoga’s quality-focused strategies. Management expressed confidence in long-term outcomes, noting that speculative leadership won’t last as monetary policy tightens and market breadth improves. The firm remains committed to high-quality growth businesses, expecting these to regain favor as leadership broadens. The Conestoga Micro-Cap Composite achieved a solid second quarter with a 22.16% net return, although it underperformed the Russell Microcap Growth Index’s 28.98% return. During this period, Micro-Cap Growth surpassed all major equity benchmarks, which reflects improved investor sentiment towards smaller-cap stocks, but the gains were primarily driven by a limited set of high-beta, high-momentum stocks. In addition, please check the Strategy’s top five holdings to know its best picks in 2026.
In its Q2 2026 investor letter, Conestoga Capital Advisors highlighted Iradimed Corporation (NASDAQ:IRMD). Iradimed Corporation (NASDAQ:IRMD), a medical device company specializing in MRI-compatible intravenous infusion pump systems and patient monitoring systems, detracted from the strategy’s performance during the quarter. On August 06, 2026, Iradimed Corporation (NASDAQ:IRMD) closed at $91.21 per share, reflecting a market capitalization of $1.16 billion. Iradimed Corporation (NASDAQ:IRMD) posted a one-month return of -6.16%, while its shares gained 30.43% over the past 52 weeks.
Conestoga Capital Advisors stated the following regarding Iradimed Corporation (NASDAQ:IRMD) in its Q2 2026 investor letter:
“Iradimed Corporation (NASDAQ:IRMD) develops MRI-compatible intravenous infusion pumps and patient monitoring systems. The stock declined despite another quarter of double-digit revenue growth as investors focused on the pace of the new 3870 pump rollout rather than the company’s solid financial performance. Management noted the replacement cycle is expected to build gradually over several quarters. We remain encouraged by the early demand for the 3870 platform and believe the replacement opportunity should support durable long-term growth.”
Iradimed Corporation (NASDAQ:IRMD) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 10 hedge fund portfolios held Iradimed Corporation (NASDAQ:IRMD) at the end of the first quarter, up from 9 in the previous quarter. While we acknowledge the risk and potential of Iradimed Corporation (NASDAQ:IRMD) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than Iradimed Corporation (NASDAQ:IRMD) and that has 10,000% upside potential, check out our report about this cheapest AI stock.
In another article, we covered Iradimed Corporation (NASDAQ:IRMD) and shared Riverwater Micro Opportunities Strategy’s insight on the company. In addition, please check out our hedge fund investor letters Q2 2026 page for more investor letters from hedge funds and other leading investors.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. This article is originally published at Insider Monkey.
